Gamechanging HIV Prevention Jab Approved for England and Wales
“`html
England to Offer Long-acting HIV prevention Injection, aiming for 2030 Transmission Elimination
Table of Contents
A new injectable treatment for HIV prevention is set to roll out in England, offering an alternative to daily oral medication (PrEP) and bolstering the nation’s aspiring goal to end new HIV transmissions by 2030.
Published: october 17, 2024
Breakthrough Treatment Approved
The National Institute for Health and Care Excellence (NICE) is expected to publish final guidance on the long-acting injectable cabotegravir later this year, paving the way for its availability to eligible individuals approximately three months after the guidance is released. The medication, administered via injection, provides two months of protection against HIV infection.
“We’re making real progress on HIV, with Prep use up by 8% this year, and our ambition goes even further,” said a government spokesperson. “England will be the first country to end HIV transmissions by 2030, and this breakthrough treatment is another powerful tool in our arsenal to reach that crucial goal.”
Addressing Barriers to PrEP Access
Currently, over 111,000 people in England access PrEP thru sexual health clinics, representing a 7% increase from the previous year, according to the UK Health Security Agency (UKHSA) data released in 2024.However, approximately 1,000 individuals are unable to take daily oral PrEP due to medical contraindications or other barriers.
Helen Knight,director of medicines evaluation at NICE,emphasized the importance of expanding prevention options. “HIV remains a serious public health challenge, but we now have powerful tools to prevent new infections,” she stated. “Around 1,000 people in England cannot have daily oral Prep due to medical contraindications or other barriers wich is why this injection offers an effective option for this community.”
NICE estimates that up to 1,000 people will benefit from the new injectable treatment annually.
Understanding PrEP and the Path to Zero Transmissions
Pre-exposure prophylaxis (PrEP) involves taking medication *before* potential exposure to HIV to prevent infection. Its highly effective when taken as prescribed. The injectable cabotegravir offers a different administration route, potentially improving adherence for those who struggle with daily pills.
England’s commitment to ending HIV transmissions by 2030 is built on a multi-pronged strategy, including:
- Increased PrEP access
- Routine HIV testing
- Rapid treatment for those diagnosed with HIV
- Raising awareness and reducing stigma
The UKHSA reports that in 2023, there were 4,884 new HIV diagnoses in the UK, a meaningful decrease from peak levels in the early 1980s, but demonstrating the continued need for prevention efforts.